Compare Stocks

Date Range: 

 Genmab A/SMERCK Kommanditgesellschaft auf AktienCureVacGenmab A/SHorizon Therapeutics Public
SymbolOTCMKTS:GNMSFOTCMKTS:MKGAFNASDAQ:CVACNASDAQ:GMABNASDAQ:HZNP
Price Information
Current Price$370.42$173.88$97.97$36.73$87.40
52 Week RangeBuyN/AHoldHoldBuy
MarketRank™
Overall Score0.60.50.71.42.6
Analysis Score0.00.01.23.24.5
Community Score1.92.32.32.93.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.01.7
Earnings & Valuation Score1.30.00.00.63.8
Analyst Ratings
Consensus RecommendationBuyN/AHoldHoldBuy
Consensus Price TargetN/AN/A$58.33$41.57$111.36
% Upside from Price TargetN/AN/A-40.46% downside13.18% upside27.42% upside
Trade Information
Market Cap$22.85 billion$22.47 billion$18.31 billion$24.09 billion$19.64 billion
Beta0.830.7N/A0.931.15
Average Volume1,230451981,217582,0441,837,838
Sales & Book Value
Annual Revenue$804.57 million$18.09 billionN/A$804.57 million$1.30 billion
Price / Sales28.401.24N/A29.9415.11
Cashflow$4.83 per share$36.99 per shareN/A$0.46 per share$3.93 per share
Price / Cash76.644.70N/A80.6422.22
Book Value$34.13 per share$155.24 per shareN/A$3.24 per share$11.67 per share
Price / Book10.851.12N/A11.347.49
Profitability
Net Income$324.68 million$1.48 billionN/A$324.68 million$573.02 million
EPSN/AN/AN/A$0.51$1.94
Trailing P/E Ratio5.260.000.0028.4723.88
Forward P/E RatioN/A66.7820.33
P/E GrowthN/AN/AN/A2.910.59
Net Margins51.02%10.92%N/A50.99%43.55%
Return on Equity (ROE)34.38%14.29%N/A34.40%25.66%
Return on Assets (ROA)30.65%5.90%N/A30.67%14.19%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.26%
Current Ratio8.64%1.06%N/A8.64%3.49%
Quick Ratio8.64%0.70%N/A8.64%3.39%
Ownership Information
Institutional Ownership Percentage0.04%N/A4.32%6.24%88.59%
Insider Ownership PercentageN/AN/AN/AN/A4.30%
Miscellaneous
Employees78158,1275007811,395
Shares Outstanding61.69 million129.24 million186.91 million655.87 million224.77 million
Next Earnings Date8/11/2021 (Estimated)5/13/2021 (Estimated)N/A8/11/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care ConferenceHorizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference
finance.yahoo.com - May 6 at 5:16 PM
New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & NeuroinflammationNew Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
finance.yahoo.com - May 6 at 12:15 PM
Horizon Therapeutics Public (NASDAQ:HZNP) Releases FY 2021 Earnings GuidanceHorizon Therapeutics Public (NASDAQ:HZNP) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 5 at 8:52 PM
Horizon Therapeutics Public (NASDAQ:HZNP) Posts Quarterly  Earnings Results, Misses Expectations By $0.16 EPSHorizon Therapeutics Public (NASDAQ:HZNP) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS
americanbankingnews.com - May 5 at 5:12 PM
An in-depth look at the Horizon Therapeutics Public Limited Company (HZNP) stockAn in-depth look at the Horizon Therapeutics Public Limited Company (HZNP) stock
marketingsentinel.com - May 5 at 4:20 PM
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Today’s Hot StockHorizon Therapeutics Public Limited Company (NASDAQ:HZNP) Today’s Hot Stock
stocksregister.com - May 5 at 4:20 PM
Horizon Therapeutics Public Limited Company 2021 Q1 - Results - Earnings Call PresentationHorizon Therapeutics Public Limited Company 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 5 at 3:08 PM
Is Horizon Therapeutics Public Limited Company (HZNP) A Smart Long-Term Buy?Is Horizon Therapeutics Public Limited Company (HZNP) A Smart Long-Term Buy?
feedproxy.google.com - May 5 at 1:12 PM
Horizon Therapeutics (HZNP) Misses Q1 Earnings EstimatesHorizon Therapeutics (HZNP) Misses Q1 Earnings Estimates
msn.com - May 5 at 11:06 AM
Horizon Therapeutics: Q1 Earnings SnapshotHorizon Therapeutics: Q1 Earnings Snapshot
sfgate.com - May 5 at 11:06 AM
Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.
finance.yahoo.com - May 5 at 11:06 AM
Was The Smart Money Right About Horizon Therapeutics (HZNP)?Was The Smart Money Right About Horizon Therapeutics (HZNP)?
finance.yahoo.com - May 4 at 2:29 PM
Horizon Therapeutics Public Limited (NASDAQ:HZNP) Expected to Announce Quarterly Sales of $356.38 MillionHorizon Therapeutics Public Limited (NASDAQ:HZNP) Expected to Announce Quarterly Sales of $356.38 Million
americanbankingnews.com - May 2 at 1:18 AM
Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase ...Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase ...
apnews.com - April 30 at 3:20 PM
Horizon Therapeutics Public (NASDAQ:HZNP) Sets New 1-Year High at $96.60Horizon Therapeutics Public (NASDAQ:HZNP) Sets New 1-Year High at $96.60
americanbankingnews.com - April 26 at 12:50 PM
At Current Prices, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Worth A Patient Look?At Current Prices, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Worth A Patient Look?
marketingsentinel.com - April 24 at 2:44 PM
We Think Shareholders Will Probably Be Generous With Horizon Therapeutics Public Limited Companys (NASDAQ:HZNP) CEO CompensationWe Think Shareholders Will Probably Be Generous With Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Compensation
nasdaq.com - April 24 at 2:44 PM
We Take A Look At Why Horizon Therapeutics Public Limited Companys (NASDAQ:HZNP) CEO Has Earned Their Pay PacketWe Take A Look At Why Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Has Earned Their Pay Packet
finance.yahoo.com - April 24 at 2:44 PM
Does Horizon Therapeutics (NASDAQ:HZNP) Have A Healthy Balance Sheet?Does Horizon Therapeutics (NASDAQ:HZNP) Have A Healthy Balance Sheet?
nasdaq.com - April 21 at 1:49 PM
HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for GoutHemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout
finance.yahoo.com - April 21 at 8:49 AM
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & EndocrinologyNew Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
finance.yahoo.com - April 16 at 9:04 AM
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
finance.yahoo.com - April 16 at 9:04 AM
Biotech Stock On Earnings Win Streak Sets Up Bullish ChartBiotech Stock On Earnings Win Streak Sets Up Bullish Chart
finance.yahoo.com - April 12 at 7:16 PM
Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
finance.yahoo.com - April 12 at 9:14 AM
Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
finance.yahoo.com - April 8 at 9:07 AM
DateCompanyBrokerageAction
11/25/2020Genmab A/SUBS GroupReiterated Rating
8/13/2020Genmab A/SBarclaysReiterated Rating
10/1/2018Genmab A/SHC WainwrightReiterated Rating
5/3/2021CureVacGuggenheimInitiated Coverage
4/26/2021CureVacCredit Suisse GroupInitiated Coverage
11/17/2020CureVacBerenberg BankReiterated Rating
9/8/2020CureVacBank of AmericaInitiated Coverage
9/8/2020CureVacJefferies Financial GroupInitiated Coverage
4/26/2021Genmab A/SMorgan StanleyLower Price Target
4/20/2021Genmab A/SDeutsche Bank AktiengesellschaftInitiated Coverage
3/15/2021Genmab A/SDNB MarketsUpgrade
3/9/2021Genmab A/SJPMorgan Chase & Co.Reiterated Rating
3/3/2021Genmab A/SSVB LeerinkLower Price Target
2/25/2021Genmab A/STruistBoost Price Target
2/24/2021Genmab A/SDanskeUpgrade
1/4/2021Genmab A/SRoyal Bank of CanadaBoost Price Target
10/27/2020Genmab A/SThe Goldman Sachs GroupBoost Price Target
3/24/2021Horizon Therapeutics PublicCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/23/2021Horizon Therapeutics PublicStifel NicolausBoost Price Target
3/17/2021Horizon Therapeutics PublicWolfe ResearchInitiated Coverage
11/3/2020Horizon Therapeutics PublicBMO Capital MarketsBoost Price Target
7/22/2020Horizon Therapeutics PublicPiper SandlerBoost Price Target
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.